Board Change • May 20
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 3 highly experienced directors. CEO & Director Owen Hughes was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Annonce • Apr 29
Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) entered into a definitive agreement to acquire XOMA Royalty Corporation (NasdaqGM:XOMA) for approximately $470 million from BVF Partners L.P. and others. Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) entered into a definitive agreement to acquire XOMA Royalty Corporation (NasdaqGM:XOMA) for approximately $470 million from BVF Partners L.P. and others on April 27, 2026. Under the terms of the merger agreement, Ligand will acquire all the outstanding shares of common stock of XOMA Royalty for $39.00 per share in cash, for a total equity value of approximately $739 million. XOMA Royalty stockholders are expected to separately receive one non-transferable Contingent Value Right per share entitling the holder to receive a portion of 75% of the net proceeds that may result from certain pending litigation at XOMA Royalty. XOMA Royalty’s Series X Convertible Preferred Stock is expected to be converted into shares of common stock at its stated fixed price prior to closing, whereas the outstanding shares of Series A Preferred Stock and Series B Preferred Stock are expected to be redeemed. XOMA Royalty stockholders also will receive one CVR per share. The CVRs are intended to provide XOMA Royalty stockholders with the opportunity to receive certain net proceeds, if any are recovered, from certain ongoing litigation with regard to XOMA Royalty’s dispute with Janssen Biotech regarding the commercialization of TREMFYA®. The cash consideration for the transaction is expected to be funded with Ligand’s existing cash on hand and borrowings under Ligand’s existing credit facility. The cash purchase price at close represents an approximately 14% premium to XOMA Royalty’s 30 trading day volume weighted average price as of April 24, 2026, the last trading day prior to announcement of the transaction. In case of termination of transaction, Ligand will pay a termination fee of $40 million.
The transaction has been unanimously approved by the Ligand and XOMA Royalty Boards of Directors. The transaction is subject to customary closing conditions, approval by XOMA Royalty stockholders, antitrust regulations, and the receipt of certain regulatory approvals. The transaction is expected to close in the third quarter of 202 and to be immediately accretive to Ligand earnings per share. Ligand is increasing its 2026 revenue guidance to be in the range of $270 million to $310 million (previously $245 million to $285 million) and is raising adjusted earnings per diluted share guidance to $8.50 to $9.50 (previously $8.00 to $9.00). Royalties are now expected to range from $225 million to $250 million (previously $200 million to $225 million). Guidance for sales of Captisol® ($35 million to $40 million) and contract revenue ($10 million to $20 million) are unchanged. In addition, Ligand expects the transaction to be accretive by $1.50 per share to adjusted EPS in 2027.
Stifel, Nicolaus & Company, Incorporated acted as lead financial advisor for Ligand Pharmaceuticals Incorporated. Citigroup Global Markets Inc. acted as financial advisor for Ligand Pharmaceuticals Incorporated. Paul Hastings LLP acted as legal advisor for Ligand Pharmaceuticals Incorporated. Leerink Partners LLC acted as lead financial advisor for XOMA Royalty Corporation. H.C. Wainwright & Co., LLC acted as financial advisor for XOMA Royalty Corporation. Gibson, Dunn & Crutcher LLP acted as legal advisor for XOMA Royalty Corporation. Collected Strategies is serving as strategic communications advisor to Ligand. Annonce • Mar 31
XOMA Royalty Corporation, Annual General Meeting, May 21, 2026 XOMA Royalty Corporation, Annual General Meeting, May 21, 2026. Annonce • Mar 12
XOMA Royalty Corporation to Report Q4, 2025 Results on Mar 18, 2026 XOMA Royalty Corporation announced that they will report Q4, 2025 results Pre-Market on Mar 18, 2026 Annonce • Jan 16
XOMA Royalty Corporation Announces Departure of Thomas Burns as Senior Vice President, Finance, Effective January 12, 2026 Effective January 12, 2026, Thomas Burns stepped down from his position as Senior Vice President, Finance and Chief Financial Officer of XOMA Royalty Corporation (the Company). Annonce • Jan 13
XOMA Royalty Corporation Announces CFO Changes XOMA Royalty Corporation announced on January 12, 2026, that its Chief Financial Officer, Thomas Burns, will be stepping down from his position with XOMA Royalty to pursue other professional opportunities. In conjunction with this leadership transition, XOMA Royalty has appointed Jeffrey Trigilio as Chief Financial Officer. Mr. Trigilio has served in a variety of financial, strategic and business development roles at numerous biotech companies and investment banks. Most recently, Mr. Trigilio served as the Chief Financial and Operating Officer of Obsidian Therapeutics, and prior to that, Chief Financial Officer at Cullinan Therapeutics. He started his operating career at Alexion Pharmaceuticals, having served in various corporate strategy and finance roles. Annonce • Dec 16
XOMA Royalty Corporation (NasdaqGM:XOMA) entered into an agreement to acquire Generation Bio Co. (NasdaqGS:GBIO) for $28.92 million. XOMA Royalty Corporation (NasdaqGM:XOMA) entered into an agreement to acquire Generation Bio Co. (NasdaqGS:GBIO) for $28.92 million on December 15, 2025. A cash consideration of $28.92 million valued at $4.2913 per share will be paid by XOMA Royalty Corporation. As part of consideration, $28.92 million is paid towards common equity of Generation Bio Co and one contingent value right per Company Share, which represents the right to receive certain payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement to be entered into by the XOMA with Broadridge Corporate Issuer Solutions, LLC. In case of termination of transaction, Generation Bio will pay a termination fee of $0.84 million.
The transaction is subject to approval of merger agreement by target board. The deal has been unanimously approved by the board. The expected completion of the transaction is February 2026, subject to the satisfaction of customary closing conditions.
Gibson, Dunn & Crutcher LLP acted as legal advisor to XOMA Royalty. TD Cowen acted served as financial advisor and provided fairness opinion, and Wilmer Cutler Pickering Hale and Dorr LLP served as legal counsel, to Generation Bio. The Depository Trust Company acted as depository bank to Generation Bio. Annonce • Dec 05
XOMA Royalty Corporation (NasdaqGM:XOMA) completed the acquisition of Mural Oncology plc (NasdaqGM:MURA) from group of shareholders. XOMA Royalty Corporation (NasdaqGM:XOMA) proposed to acquire Mural Oncology plc (NasdaqGM:MURA) from group of shareholders on June 9, 2025. XOMA Royalty Corporation entered into a definitive agreement to acquire Mural Oncology plc from group of shareholders for $36.2 million on August 20, 2025. A cash consideration valued at $2.035 per share will be paid by XOMA Royalty Corporation for 17.324771 million shares. XOMA Royalty Corporation will pay additional cash amount per share of up to $0.205 for $3.56 million in cash. Pursuant to the terms of the Transaction Agreement and subject to certain conditions and the closing of the Acquisition shareholders (i) are entitled to receive a base cash price of $2.035 per share, which has been calculated on the basis of the Company having approximately $36.2 million of closing net cash and is payable to the Company’s shareholders at the Closing regardless of the actual amount of the Company’s closing net cash on or before the Closing, and (ii) may receive an additional cash amount per share of up to $0.205. The Consideration payable under the terms of the Acquisition will be funded by XOMA Royalty’s existing cash and cash equivalent resources.
The transaction is subject to approval of offer by target shareholders, subject to antitrust regulations, all required Clearances of any Governmental Entity and subject to sanction of the Irish High Court. The transaction has been approved by board of Mural Oncology and XOMA Royalty. The transaction is expected to close in fourth quarter of 2025. On October 24, 2025, the shareholders of Mural Oncology plc has approved the transaction. As of November 26, 2025, the transaction is expected to close in early December 2025.
Lucid Capital Markets, LLC acted as financial advisor and fairness opinion provider to Mural Oncology plc and and will be paid a fee of $0.45 million. Ryan A. Murr and Branden C. Berns of Gibson, Dunn & Crutcher LLP acted as legal advisor for XOMA Royalty Corporation. Justin McKenna and Anne Harkin of Mason Hayes & Curran Solicitors acted as legal advisor for XOMA Royalty Corporation. Christopher McLaughlin and David Vos of Arthur Cox LLP acted as legal advisor for Mural Oncology plc. Stuart M. Falber, Mark Nylen and Scott Lunin of Wilmer Cutler Pickering Hale and Dorr LLP acted as legal advisor for Mural Oncology plc. MacKenzie Partners, Inc. acted as information agent/proxy solicitor to Mural Oncology plc and will be paid a fee of $0.01 million.
XOMA Royalty Corporation (NasdaqGM:XOMA) completed the acquisition of Mural Oncology plc (NasdaqGM:MURA) from group of shareholders December 4, 2025. On December 3, 2025, the High Court sanctioned the Scheme. Annonce • Oct 04
XOMA Royalty Corporation has filed a Follow-on Equity Offering in the amount of $75 million. XOMA Royalty Corporation has filed a Follow-on Equity Offering in the amount of $75 million.
Security Name: Common Stock
Security Type: Common Stock
Transaction Features: At the Market Offering Annonce • Sep 18
XOMA Royalty Corporation (NasdaqGM:XOMA) completed the acquisition of HilleVax, Inc. (NasdaqGS:HLVX). XOMA Royalty Corporation (NasdaqGM:XOMA) entered into an Agreement and Plan of Merger to acquire HilleVax, Inc. (NasdaqGS:HLVX) for $97.8 million on August 4, 2025. Under the terms of the Merger Agreement, HilleVax stockholders will receive $1.95 in cash per share of HilleVax common stock at the closing of the merger, plus one non-transferable contingent value right. Pursuant and subject to the terms of the Merger Agreement, XOMA Royalty and its acquisition subsidiary will commence a tender offer by August 18, 2025, to acquire all outstanding shares of HilleVax common stock. Sell side termination fee is $2.475 million. The closing of the Offer is subject to certain conditions, including the tender of HilleVax common stock representing at least a majority of the total number of outstanding shares; a minimum cash balance at closing, and other customary closing conditions. Immediately following the closing of the tender offer, HilleVax will be acquired by XOMA Royalty, and all remaining shares not tendered in the offer, other than shares validly subject to appraisal, will be converted into the right to receive the same cash and CVR consideration per share as is provided in the tender offer. Certain HilleVax officers, directors and stockholders holding approximately 22.9% of HilleVax common stock have signed support agreements under which such stockholders have agreed to tender their shares in the Offer and support the merger transaction.
HilleVax’s Board of Directors has unanimously approved the transaction. The closing net cash of the Company as finally determined pursuant to the Merger Agreement shall be no less than $102.95 million. The acquisition is expected to close in September 2025. As on September 15, 2025, the Offer expired and 77.48% of Shares were validly tendered.
Leerink Partners is acting as exclusive financial advisor and fairness opinion provider to HilleVax and Daniel Rees, Matthew Bush, Betty Pang, Chad Jennings, Chris Hazuka, Eric Cho, Holly Bauer, Sara Schlau and Heather Deixler of Latham & Watkins LLP is acting as legal counsel to HilleVax. Ryan A. Murr and Branden C. Berns of Gibson, Dunn & Crutcher LLP is acting as legal counsel to XOMA Royalty.
XOMA Royalty Corporation (NasdaqGM:XOMA) completed the acquisition of HilleVax, Inc. (NasdaqGS:HLVX) on September 17, 2025. Annonce • Aug 20
XOMA Royalty Corporation (NasdaqGM:XOMA) entered into a definitive agreement to acquire Mural Oncology plc (NasdaqGM:MURA) for $35.3 million. XOMA Royalty Corporation (NasdaqGM:XOMA) proposed to acquire Mural Oncology plc (NasdaqGM:MURA) on June 9, 2025. XOMA Royalty Corporation entered into a definitive agreement to acquire Mural Oncology plc for $35.3 million on August 20, 2025. A cash consideration valued at $2.035 per share will be paid by XOMA Royalty Corporation for 17.324771 million shares. XOMA Royalty Corporation will pay an earnout/contingent payment of $3.56 million cash. Pursuant to the terms of the Transaction Agreement and subject to certain conditions and the closing of the Acquisition shareholders (i) are entitled to receive a base cash price of $2.035 per share, which has been calculated on the basis of the Company having approximately $36.2 million of closing net cash and is payable to the Company’s shareholders at the Closing regardless of the actual amount of the Company’s closing net cash on or before the Closing, and (ii) may receive an additional cash amount per share of up to $0.205. The Consideration payable under the terms of the Acquisition will be funded by XOMA Royalty’s existing cash and cash equivalent resources.
The transaction is subject to approval of offer by target shareholders, subject to antitrust regulations, all required Clearances of any Governmental Entity and subject to court approval. The transaction has been approved by board of Mural Oncology and XOMA Royalty. The transaction is expected to close in fourth quarter of 2025.
Lucid Capital Markets, LLC acted as financial advisor for Mural Oncology plc. Gibson, Dunn & Crutcher LLP acted as legal advisor for XOMA Royalty Corporation. Mason Hayes & Curran Solicitors acted as legal advisor for XOMA Royalty Corporation. Christopher McLaughlin and David Vos of Arthur Cox LLP acted as legal advisor for Mural Oncology plc. Stuart M. Falber, Mark Nylen and Scott Lunin of Wilmer Cutler Pickering Hale and Dorr LLP acted as legal advisor for Mural Oncology plc. Annonce • Aug 11
XOMA Royalty Corporation (NasdaqGM:XOMA) completed the acquisition of Turnstone Biologics Corp. (NasdaqCM:TSBX). XOMA Royalty Corporation (NasdaqGM:XOMA) agreed to acquire Turnstone Biologics Corp. (NasdaqCM:TSBX) on June 27, 2025. Turnstone will be required to pay XOMA a termination fee of $350,000. If XOMA terminates the Merger Agreement due to the failure of the Closing Net Cash Condition, the Company will be required to pay to XOMA an expense reimbursement fee up to a maximum amount of $350,000.
Turnstone Board of Directors has unanimously determined that the acquisition by XOMA Royalty is in the best interests of all Turnstone stockholders and has approved the transaction. The closing of the Offer is subject to certain conditions, including the tender of Turnstone common stock representing at least a majority of the total number of outstanding shares, a minimum cash balance at closing, and other customary closing conditions.
Pursuant and subject to the terms of the MergerAgreement, XOMA Royalty will commence a tender offer (the "Offer") by July 11, 2025, to acquire all outstanding shares of Turnstone common stock. Immediately following the closing of the tender offer, Turnstone will be acquired by XOMA Royalty, and all remainingshares not tendered in the offer, other than shares validly subject to appraisal, will be converted into the right to receive the same cash and CVR consideration per share as is provided in the tender offer.
Leerink Partners is acting as financial advisor and Divakar Gupta and Rama Padmanabhan of Cooley LLP is acting as legal counsel to Turnstone. Ryan A. Murr and Branden C. Berns of Gibson, Dunn & Crutcher LLP is acting as legal counsel to XOMA Royalty.
XOMA Royalty Corporation (NasdaqGM:XOMA) completed the acquisition of Turnstone Biologics Corp. (NasdaqCM:TSBX) on August 11, 2025. As of the Expiration Date, a total of 17,192,002 shares of Turnstone common stock were validly tendered, and not validly withdrawn, representing approximately 74% of the outstanding shares of Turnstone common stock as of the Expiration Date. Annonce • Aug 05
XOMA Royalty Corporation (NasdaqGM:XOMA) entered into an Agreement and Plan of Merger to acquire HilleVax, Inc. (NasdaqGS:HLVX) for $97.8 million. XOMA Royalty Corporation (NasdaqGM:XOMA) entered into an Agreement and Plan of Merger to acquire HilleVax, Inc. (NasdaqGS:HLVX) for $97.8 million on August 4, 2025. Under the terms of the Merger Agreement, HilleVax stockholders will receive $1.95 in cash per share of HilleVax common stock at the closing of the merger, plus one non-transferable contingent value right. Pursuant and subject to the terms of the Merger Agreement, XOMA Royalty and its acquisition subsidiary will commence a tender offer by August 18, 2025, to acquire all outstanding shares of HilleVax common stock. Sell side termination fee is $2.475 million. The closing of the Offer is subject to certain conditions, including the tender of HilleVax common stock representing at least a majority of the total number of outstanding shares; a minimum cash balance at closing, and other customary closing conditions. Immediately following the closing of the tender offer, HilleVax will be acquired by XOMA Royalty, and all remaining shares not tendered in the offer, other than shares validly subject to appraisal, will be converted into the right to receive the same cash and CVR consideration per share as is provided in the tender offer. Certain HilleVax officers, directors and stockholders holding approximately 22.9% of HilleVax common stock have signed support agreements under which such stockholders have agreed to tender their shares in the Offer and support the merger transaction. HilleVax’s Board of Directors has unanimously approved the transaction. The closing net cash of the Company as finally determined pursuant to the Merger Agreement shall be no less than $102.95 million. The acquisition is expected to close in September 2025. Leerink Partners is acting as exclusive financial advisor and fairness opinion provider to HilleVax and Daniel Rees and Matt Bush of Latham & Watkins LLP is acting as legal counsel to HilleVax. Ryan A. Murr and Branden C. Berns of Gibson, Dunn & Crutcher LLP is acting as legal counsel to XOMA Royalty. Annonce • Aug 04
XOMA Royalty Corporation (NasdaqGM:XOMA) entered a definitive share purchase agreement to acquire LAVA Therapeutics N.V. (NasdaqGS:LVTX) for $32.6 million. XOMA Royalty Corporation (NasdaqGM:XOMA) entered a definitive share purchase agreement to acquire LAVA Therapeutics N.V. (NasdaqGS:LVTX) for $32.6 million on August 3, 2025. XOMA Royalty will acquire LAVA for between $1.16 and $1.24 per share in cash, consisting of $1.16 (the “Base Price Per Share”) in cash per share (the “LAVA common stock”), plus an additional amount of cash of up to $0.08 per Share agreed-upon determination of Closing Net Cash on 10th Business Day before each then scheduled Expiration Time (such amount as finally determined in accordance with the Purchase Agreement, the “Additional Price Per Share,” and together with the Base Price Per Share, the “Cash Amount”), plus one non-transferable contingent value right (“CVR”) per share representing the right to receive 75% of the net proceeds related to LAVA’s two partnered assets and 75% of any net proceeds from any out license or sale of LAVA’s unpartnered programs. LAVA will be required to pay XOMA a termination fee of $750,000. Following a subsequent offering period, LAVA will undergo a corporate reorganization designed to result in XOMA Royalty acquiring 100% of the shares in LAVA’s successor and all then-remaining LAVA shareholders (other than XOMA Royalty) receiving the same cash and CVR consideration per share as is provided in the tender offer, subject to applicable withholding taxes. LAVA will hold a shareholder’s meeting in connection with the Transactions. XOMA Royalty will commence a tender offer by August 15, 2025, to acquire all outstanding shares of LAVA common stock. As a result of the Post-Offer Reorganization, LAVA will no longer be a publicly traded company, the listing of the Shares on Nasdaq Stock Market LLC will be terminated and the Shares will be deregistered under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), resulting in the cessation of LAVA's reporting obligations with respect to the Shares thereunder.
The transaction is to any applicable law or order entered, enacted, promulgated, enforced, or issued by any court or other governmental authority of competent jurisdiction prohibiting, rendering illegal, or enjoining the consummation of the Transactions; the accuracy of representations and warranties made by LAVA in the Purchase Agreement, subject compliance in all material respects by LAVA with its obligations under the Purchase Agreement, shareholders have adopted resolutions related appointing Buyer’s designees to the Board and certain transactions pursuant, the Closing Net Cash shall be no less than the amount specified in the Purchase Agreement and no termination of the Purchase Agreement. Buyer is not required to extend the Offer beyond December 31, 2025. In addition, if the only unmet Offer Condition is the Minimum Condition, Buyer may, but is not required to, extend the Offer on more than two occasions in consecutive periods of up to 10 business days. The closing of the Transactions is expected in the fourth quarter of 2025. LAVA’s Board unanimously recommends that shareholders support the Offer, accept the Offer and vote in favor of the resolutions to be proposed to LAVA’s shareholders’ meeting.
Ryan A. Murr and Branden Berns of Gibson, Dunn & Crutcher LLP and Michel van Agt and Menno Baks of Loyens & Loeff N.V. acted as legal advisors for XOMA Royalty Corporation. Kevin Cooper and Rita Sobral of Cooley LLP and Paul van der Bijl of NautaDutilh N.V. acted as legal advisors and Leerink Partners LLC acted as financial advisor for LAVA Therapeutics N.V. Annonce • Jun 27
XOMA Royalty Corporation (NasdaqGM:XOMA) agreed to acquire Turnstone Biologics Corp. XOMA Royalty Corporation (NasdaqGM:XOMA) agreed to acquire Turnstone Biologics Corp. (NasdaqCM:TSBX) on June 27, 2025.
Turnstone Board of Directors has unanimously determined that the acquisition by XOMA Royalty is in the best interests of all Turnstone stockholders and has approved the transaction. The closing of the Offer is subject to certain conditions, including the tender of Turnstone common stock representing at least a majority of the total number of outstanding shares, a minimum cash balance at closing, and other customary closing conditions.
Pursuant and subject to the terms of the MergerAgreement, XOMA Royalty will commence a tender offer (the "Offer") by July 11, 2025, to acquire all outstanding shares of Turnstone common stock. Immediately following the closing of the tender offer, Turnstone will be acquired by XOMA Royalty, and all remainingshares not tendered in the offer, other than shares validly subject to appraisal, will be converted into the right to receive the same cash and CVR consideration per share as is provided in the tender offer.
Leerink Partners is acting as financial advisor and Cooley LLP is acting as legal counsel to Turnstone. Gibson, Dunn & Crutcher LLP is acting as legal counsel to XOMA Royalty. Annonce • May 31
XOMA Royalty Corporation Approves Amendment to the By-Laws On May 21, 2025, XOMA Royalty Corporation (Company) convened its 2025 Annual Meeting of Stockholders, which was adjourned until May 28, 2025, approved proposal to Authorize the Board to Unilaterally Amend the By-laws. Annonce • Apr 07
XOMA Royalty Corporation, Annual General Meeting, May 21, 2025 XOMA Royalty Corporation, Annual General Meeting, May 21, 2025. Annonce • Dec 03
XOMA Royalty Corporation (NasdaqGM:XOMA) acquired Pulmokine, Inc. for $45 million. XOMA Royalty Corporation (NasdaqGM:XOMA) acquired Pulmokine, Inc. for $45 million on December 2, 2024. In addition, the Company will pay success-based consideration contingent on future development and commercial events to Target stockholders. The Company’s net royalties will range from the low to mid-single digits on commercial sales; additionally, the Company will retain up to $25 million of future milestone payments related to seralutinib, a Phase 3 asset. Gibson, Dunn & Crutcher LLP acted as legal advisor for XOMA Royalty Corporation.
XOMA Royalty Corporation (NasdaqGM:XOMA) completed the acquisition of Pulmokine, Inc. on December 2, 2024 Major Estimate Revision • May 16
Consensus revenue estimates increase by 64% The consensus outlook for revenues in fiscal year 2024 has improved. 2024 revenue forecast increased from US$14.0m to US$22.9m. Forecast losses expected to reduce from -US$2.38 to -US$2.28 per share. Biotechs industry in the US expected to see average net income decline 9.7% next year. Consensus price target of US$58.00 unchanged from last update. Share price rose 4.3% to US$24.71 over the past week. Reported Earnings • May 10
First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2024 results: US$0.86 loss per share (improved from US$0.98 loss in 1Q 2023). Net loss: US$9.96m (loss narrowed 11% from 1Q 2023). Revenue exceeded analyst estimates by 11%. Earnings per share (EPS) missed analyst estimates by 6.2%. Revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 96 percentage points per year, which is a significant difference in performance. Annonce • Apr 04
XOMA Corporation (NasdaqGM:XOMA) completed the acquisition of Kinnate Biopharma Inc. (NasdaqGS:KNTE). XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million on February 16, 2024. XOMA will acquire Kinnate for a price per share of Kinnate common stock of between $2.3352 and $2.5879 in cash, consisting of (i) a base cash price of $2.3352 per share and (ii) an additional cash amount of up to $0.2527 per share, plus one non-transferable contingent value right per share, representing the right to receive (a) 100% of the net proceeds payable from any disposition of Kinnate’s investigational pan-RAF inhibitor, exarafenib, and/or any other pan-RAF inhibitors prior to the closing of the merger transaction and (b) 85% of the net proceeds payable from any disposition of other Kinnate assets entered into prior to, or within one year from, closing and received within five years of closing pursuant to a definitive contingent value rights agreement. XOMA will commence a tender offer by March 4, 2024 to acquire all outstanding shares of Kinnate common stock. If the Merger Agreement is terminated under certain circumstances, Kinnate will be required to pay XOMA a termination fee of approximately $3.5 million
The transaction is subject to conditions, including: that the number of shares of Common Stock validly tendered (and not properly withdrawn) prior to the expiration of the Offer equals at least one share more than 50% of all shares of Common Stock then issued and outstanding as of the expiration of the Offer; XOMA accepted for payment all shares of Kinnate Common Stock validly tendered and not properly withdrawn pursuant to the Offer; and the Closing Net Cash shall be no less than approximately $120 million. The transaction is not subject to a financing condition. Kinnate’s Board of Directors unanimously approved the transaction. Board of Directors of XOMA also approved the transaction. The transaction is expected to close in the first half of 2024. As of March 19, 2024, the acquisition is expected to close in April 2024.
Leerink Partners is acting as lead financial advisor and fairness opinion provider and Tony Jeffries, Robert T. Ishii and Brendan Ripley Mahan of Wilson Sonsini Goodrich & Rosati is acting as legal counsel to Kinnate. Lazard is also acting as a financial advisor to Kinnate. Ryan A. Murr and Robert Phillips of Gibson, Dunn & Crutcher LLP acted as legal advisor to XOMA. The Depository Trust Company is acting as depository bank for Kinnate.
XOMA Corporation (NasdaqGM:XOMA) completed the acquisition of Kinnate Biopharma Inc. (NasdaqGS:KNTE) on April 3, 2024. All conditions to the Offer, including the Minimum Tender Condition, having been satisfied or waived, Purchaser irrevocably accepted for payment, and made payment for all Shares validly tendered and not validly withdrawn in the Offer. Annonce • Apr 03
XOMA Corporation, Annual General Meeting, May 15, 2024 XOMA Corporation, Annual General Meeting, May 15, 2024, at 09:00 Pacific Standard Time. Agenda: To elect the seven director nominees named in the proxy statement to serve until the 2025 annual meeting of stockholders and until their successors are duly elected and qualified; to ratify the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024; and to consider and transact such other business as may properly come before the meeting or any adjournments or postponements thereof. Reported Earnings • Mar 10
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: US$4.04 loss per share (further deteriorated from US$1.98 loss in FY 2022). Net loss: US$46.3m (loss widened 105% from FY 2022). Revenue missed analyst estimates by 27%. Earnings per share (EPS) also missed analyst estimates by 97%. Revenue is forecast to grow 36% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 91 percentage points per year, which is a significant difference in performance. New Risk • Mar 09
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 1.8% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 1.8% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$17m net loss in 3 years). Revenue is less than US$5m (US$4.4m revenue). Annonce • Jan 03
XOMA Corporation (NasdaqGM:XOMA) announces an Equity Buyback for $50 million worth of its shares. XOMA Corporation (NasdaqGM:XOMA) announces a share repurchase program. Under the program, the company will repurchase up to $50 million worth of its common stock through January 2027. Reported Earnings • Nov 09
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Third quarter 2023 results: US$0.60 loss per share (further deteriorated from US$0.48 loss in 3Q 2022). Net loss: US$6.88m (loss widened 24% from 3Q 2022). Revenue missed analyst estimates by 30%. Earnings per share (EPS) also missed analyst estimates by 25%. Revenue is forecast to grow 46% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 59 percentage points per year, which is a significant difference in performance. New Risk • Nov 08
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 0.3% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 0.3% per year for the foreseeable future. Minor Risk Revenue is less than US$5m (US$4.0m revenue). Major Estimate Revision • Aug 15
Consensus revenue estimates fall by 58% The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from US$12.2m to US$5.15m. Forecast losses increased from -US$1.70 to -US$2.00 per share. Biotechs industry in the US expected to see average net income decline 13% next year. Consensus price target up from US$69.00 to US$74.00. Share price was steady at US$15.82 over the past week. Reported Earnings • Aug 08
Second quarter 2023 earnings released: US$0.59 loss per share (vs US$0.53 loss in 2Q 2022) Second quarter 2023 results: US$0.59 loss per share (further deteriorated from US$0.53 loss in 2Q 2022). Net loss: US$6.77m (loss widened 12% from 2Q 2022). Revenue is forecast to grow 38% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. Reported Earnings • May 10
First quarter 2023 earnings: EPS and revenues miss analyst expectations First quarter 2023 results: US$0.98 loss per share (further deteriorated from US$0.32 loss in 1Q 2022). Net loss: US$11.2m (loss widened 207% from 1Q 2022). Revenue missed analyst estimates by 43%. Earnings per share (EPS) also missed analyst estimates by 98%. Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 9% per year whereas the company’s share price has fallen by 7% per year. Major Estimate Revision • Mar 16
Consensus revenue estimates fall by 33% The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from US$14.3m to US$9.55m. Forecast losses increased from -US$0.32 to -US$0.96 per share. Biotechs industry in the US expected to see average net income decline 49% next year. Consensus price target of US$69.00 unchanged from last update. Share price fell 8.5% to US$20.33 over the past week. Reported Earnings • Mar 10
Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat Full year 2022 results: US$1.50 loss per share (down from US$0.69 profit in FY 2021). Net loss: US$17.1m (down 320% from profit in FY 2021). Revenue exceeded analyst estimates by 7.6%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jan 05
Investor sentiment improved over the past week After last week's 19% share price gain to US$21.83, the stock trades at a trailing P/E ratio of 25.5x. Average forward P/E is 12x in the Biotechs industry in the US. Total loss to shareholders of 13% over the past three years. Valuation Update With 7 Day Price Move • Dec 01
Investor sentiment deteriorated over the past week After last week's 17% share price decline to US$21.17, the stock trades at a trailing P/E ratio of 24.8x. Average forward P/E is 9x in the Biotechs industry in the US. Total loss to shareholders of 12% over the past three years. Major Estimate Revision • Nov 24
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 expected loss increased from -US$1.35 to -US$1.96 per share. Revenue forecast of US$5.60m unchanged since last update. Biotechs industry in the US expected to see average net income decline 93% next year. Consensus price target of US$62.50 unchanged from last update. Share price rose 41% to US$25.45 over the past week. Price Target Changed • Nov 17
Price target increased to US$62.50 Up from US$44.67, the current price target is an average from 2 analysts. New target price is 246% above last closing price of US$18.04. Stock is down 26% over the past year. The company is forecast to post a net loss per share of US$1.35 compared to earnings per share of US$0.69 last year. Major Estimate Revision • Nov 10
Consensus revenue estimates fall by 65% The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from US$16.2m to US$5.60m. Forecast losses increased from -US$0.71 to -US$1.35 per share. Biotechs industry in the US expected to see average net income decline 80% next year. Consensus price target of US$62.50 unchanged from last update. Share price was steady at US$17.65 over the past week. Reported Earnings • Nov 04
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Third quarter 2022 results: US$0.48 loss per share (improved from US$0.51 loss in 3Q 2021). Revenue: US$451.0k (down 52% from 3Q 2021). Net loss: US$5.55m (loss narrowed 4.4% from 3Q 2021). Revenue missed analyst estimates by 90%. Earnings per share (EPS) also missed analyst estimates by 109%. Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 05
Second quarter 2022 earnings: EPS and revenues miss analyst expectations Second quarter 2022 results: US$0.53 loss per share (down from US$0.31 loss in 2Q 2021). Revenue: US$983.0k (up 9.1% from 2Q 2021). Net loss: US$6.04m (loss widened 71% from 2Q 2021). Revenue missed analyst estimates by 77%. Earnings per share (EPS) also missed analyst estimates by 224%. Over the next year, revenue is expected to shrink by 38% compared to a 46% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jul 23
Investor sentiment deteriorated over the past week After last week's 21% share price decline to US$23.48, the stock trades at a trailing P/E ratio of 22.3x. Average forward P/E is 10x in the Biotechs industry in the US. Total returns to shareholders of 24% over the past three years. Recent Insider Transactions Derivative • Jul 20
CEO & Chairman of the Board exercised options and sold US$645k worth of stock On the 15th of July, James Neal exercised 25k options at a strike price of around US$4.03 and sold these shares for an average price of US$29.84 per share. This trade did not impact their existing holding. For the year to December 2015, James' total compensation was 17% salary and 83% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2022, James has owned 11.82k shares directly. Company insiders have collectively sold US$2.4m more than they bought, via options and on-market transactions in the last 12 months. Valuation Update With 7 Day Price Move • Jul 08
Investor sentiment improved over the past week After last week's 32% share price gain to US$27.46, the stock trades at a trailing P/E ratio of 26x. Average forward P/E is 10x in the Biotechs industry in the US. Total returns to shareholders of 58% over the past three years. Valuation Update With 7 Day Price Move • Jun 07
Investor sentiment improved over the past week After last week's 16% share price gain to US$21.13, the stock trades at a trailing P/E ratio of 20x. Average forward P/E is 10x in the Biotechs industry in the US. Total returns to shareholders of 26% over the past three years. Major Estimate Revision • May 18
Consensus revenue estimates fall by 14% The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from US$24.2m to US$20.8m. Forecast loss of -US$0.37, down from profit of US$0.02 per share profit previously. Biotechs industry in the US expected to see average net income decline 52% next year. Consensus price target of US$62.50 unchanged from last update. Share price rose 4.8% to US$17.86 over the past week. Major Estimate Revision • May 12
Consensus revenue estimates increase by 12% The consensus outlook for revenues in 2022 has improved. 2022 revenue forecast increased from US$21.7m to US$24.2m. Now expected to report a profit of US$0.02 instead of losses of -US$0.82 per share. Biotechs industry in the US expected to see average net income decline 44% next year. Consensus price target of US$62.50 unchanged from last update. Share price was steady at US$18.24 over the past week. Reported Earnings • May 06
First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind First quarter 2022 results: US$0.32 loss per share (up from US$0.70 loss in 1Q 2021). Revenue: US$3.11m (up US$2.73m from 1Q 2021). Net loss: US$3.65m (loss narrowed 54% from 1Q 2021). Revenue missed analyst estimates by 1.8%. Earnings per share (EPS) exceeded analyst estimates by 40%. Over the next year, revenue is expected to shrink by 25% compared to a 41% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 86% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Price Target Changed • Apr 27
Price target increased to US$62.50 Up from US$44.67, the current price target is an average from 3 analysts. New target price is 203% above last closing price of US$20.65. Stock is down 45% over the past year. The company is forecast to post a net loss per share of US$0.82 compared to earnings per share of US$0.69 last year. Buying Opportunity • Apr 11
Now 24% undervalued Over the last 90 days, the stock is up 3.9%. The fair value is estimated to be US$33.65, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 45% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 14% per annum. Earnings is forecast to decline by 27% per annum over the same time period. Valuation Update With 7 Day Price Move • Mar 15
Investor sentiment improved over the past week After last week's 21% share price gain to US$25.96, the stock trades at a forward P/E ratio of 51x. Average forward P/E is 8x in the Biotechs industry in the US. Total returns to shareholders of 76% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$33.10 per share. Buying Opportunity • Mar 11
Now 20% undervalued Over the last 90 days, the stock is up 28%. The fair value is estimated to be US$32.91, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 45% per annum over the last 3 years. The company has become profitable over the last 3 years. Reported Earnings • Mar 10
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2021 results: EPS: US$1.40 (up from US$0.82 in FY 2020). Revenue: US$38.2m (up 30% from FY 2020). Net income: US$15.8m (up 80% from FY 2020). Profit margin: 41% (up from 30% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.1%. Earnings per share (EPS) missed analyst estimates by 36%. Over the next year, revenue is expected to shrink by 11% compared to a 59% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth. Reported Earnings • Mar 10
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2021 results: EPS: US$1.40 (up from US$0.82 in FY 2020). Revenue: US$38.2m (up 30% from FY 2020). Net income: US$15.8m (up 80% from FY 2020). Profit margin: 41% (up from 30% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.1%. Earnings per share (EPS) missed analyst estimates by 36%. Over the next year, revenue is expected to shrink by 11% compared to a 59% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth. Reported Earnings • Nov 06
Third quarter 2021 earnings released: US$0.51 loss per share (vs US$0.098 loss in 3Q 2020) The company reported a mediocre third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: US$940.0k (up 69% from 3Q 2020). Net loss: US$5.80m (loss widened 439% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Oct 12
Investor sentiment improved over the past week After last week's 18% share price gain to US$27.57, the stock trades at a trailing P/E ratio of 55.2x. Average forward P/E is 13x in the Biotechs industry in the US. Total returns to shareholders of 82% over the past three years. Price Target Changed • Oct 10
Price target increased to US$49.00 Up from US$44.67, the current price target is an average from 4 analysts. New target price is 90% above last closing price of US$25.78. Stock is up 30% over the past year. Price Target Changed • Sep 08
Price target decreased to US$46.00 Down from US$52.33, the current price target is an average from 4 analysts. New target price is 81% above last closing price of US$25.38. Stock is up 29% over the past year. Valuation Update With 7 Day Price Move • Sep 07
Investor sentiment deteriorated over the past week After last week's 19% share price decline to US$25.26, the stock trades at a trailing P/E ratio of 49.9x. Average forward P/E is 14x in the Biotechs industry in the US. Total returns to shareholders of 49% over the past three years. Valuation Update With 7 Day Price Move • Aug 19
Investor sentiment deteriorated over the past week After last week's 19% share price decline to US$25.80, the stock trades at a trailing P/E ratio of 51x. Average forward P/E is 12x in the Biotechs industry in the US. Total returns to shareholders of 50% over the past three years. Major Estimate Revision • Aug 19
Consensus revenue estimates fall to US$9.98m The consensus outlook for revenues in 2021 has deteriorated. 2021 revenue forecast decreased from US$12.3m to US$9.98m. Forecast losses increased from -US$0.83 to -US$1.04 per share. Biotechs industry in the US expected to see average net income decline 26% next year. Consensus price target of US$52.33 unchanged from last update. Share price fell 19% to US$25.80 over the past week. Major Estimate Revision • Aug 12
Consensus EPS estimates increase to -US$0.83 The consensus outlook for earnings per share (EPS) in 2021 has improved. 2021 revenue forecast increased from US$11.3m to US$12.3m. EPS estimate increased from -US$1.22 to -US$0.83. Biotechs industry in the US expected to see average net income decline 21% next year. Consensus price target of US$52.33 unchanged from last update. Share price rose 2.2% to US$31.16 over the past week. Reported Earnings • Aug 06
Second quarter 2021 earnings released: US$0.31 loss per share (vs US$0.33 loss in 2Q 2020) The company reported a solid second quarter result with improved revenues and control over costs, although losses were not reduced. Second quarter 2021 results: Revenue: US$901.0k (up 103% from 2Q 2020). Net loss: US$3.53m (flat on 2Q 2020). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth. Price Target Changed • Jul 02
Price target increased to US$52.33 Up from US$46.00, the current price target is an average from 4 analysts. New target price is 56% above last closing price of US$33.49. Stock is up 67% over the past year. Recent Insider Transactions • Jul 02
CEO & Director recently sold US$303k worth of stock On the 25th of June, James Neal sold around 9k shares on-market at roughly US$33.62 per share. This was the largest sale by an insider in the last 3 months. This was James' only on-market trade for the last 12 months. Valuation Update With 7 Day Price Move • Jun 28
Investor sentiment improved over the past week After last week's 17% share price gain to US$35.47, the stock trades at a trailing P/E ratio of 69.4x. Average forward P/E is 13x in the Biotechs industry in the US. Total returns to shareholders of 70% over the past three years. Major Estimate Revision • May 13
Consensus EPS estimates fall to -US$1.00 The consensus outlook for earnings per share (EPS) in 2021 has deteriorated. 2021 revenue forecast decreased from US$12.2m to US$11.4m. Losses expected to increase from -US$0.28 to -US$1.00. Biotechs industry in the US expected to see average net income decline 15% next year. Consensus price target of US$48.50 unchanged from last update. Share price fell 12% to US$30.02 over the past week. Reported Earnings • May 07
First quarter 2021 earnings released: US$0.70 loss per share (vs US$0.49 loss in 1Q 2020) The company reported a poor first quarter result with increased losses, weaker revenues and weaker control over costs. First quarter 2021 results: Revenue: US$375.0k (down 53% from 1Q 2020). Net loss: US$7.90m (loss widened 66% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Mar 31
Investor sentiment improved over the past week After last week's 16% share price gain to US$40.00, the stock trades at a trailing P/E ratio of 48.6x. Average forward P/E is 14x in the Biotechs industry in the US. Total returns to shareholders of 92% over the past three years. Recent Insider Transactions Derivative • Mar 19
Key Executive exercised options to buy US$212k worth of stock. On the 15th of March, W. Van Ness exercised options to buy 6k shares at a strike price of around US$10.41, costing a total of US$59k. This transaction amounted to 57% of their direct individual holding at the time of the trade. Since March 2020, Van Ness has owned 9.95k shares directly. Company insiders have collectively sold US$2.7m more than they bought, via options and on-market transactions in the last 12 months. Major Estimate Revision • Mar 17
Consensus revenue estimates increase to US$17.1m The consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$11.0m to US$17.1m. Forecast losses expected to reduce from -US$0.30 to -US$0.15 per share. Biotechs industry in the US expected to see average net income growth of 4.2% next year. Consensus price target of US$46.00 unchanged from last update. Share price rose 3.7% to US$39.02 over the past week. 
